Novartis bags paediatric FDA label expansion for Lutathera
Novartis has received a US Food and Drug Administration (FDA) approval for the label expansion of its peptide receptor radionuclide…
Novartis has received a US Food and Drug Administration (FDA) approval for the label expansion of its peptide receptor radionuclide…
Sanofi’s rilzabrutinib has found success and met the primary endpoint in the Phase III LUNA trial in heavily pre-treated immune…
UK-based Chiesi has invested in reducing its carbon footprint, with the development of a new inhaler propellant and the purchase…
The US Food and Drug Administration (FDA) has granted a label expansion to Roche’s Alecensa (alectinib) as an adjuvant therapy…
US-based ABVC BioPharma has sold the rights to its botanical drug extract therapy, BLEX 404, for the treatment of non-small…
Ultimovacs has implemented cash-saving strategies, including a 40% workforce reduction, to extend its reserves into Q4 2025. The operational adjustments…
The US Food and Drug Administration (FDA) has placed a clinical hold on the Phase I trial of Neumora Therapeutics’…
US-based Portage Biotech is cash-strapped and has started looking for strategic alternatives including a wind-down of the company. The company…
Century Therapeutics has acquired US-based Clade Therapeutics, which specialises in allogeneic cell therapies, to expand its pipeline of cancer and…
OSE Immunotherapeutics has received €8.4m ($9m) in non-dilutive funding from the ‘France 2030’ plan funded by the French Government. The…